

* Nivolumab als Monotherapie ist in der EU nicht zugelassen für Patient:innen mit mCRC (dMMR/MSI-H).

1. Elez E, et al. Nivolumab + ipilimumab vs nivolumab in microsatellite instability high/mismatch repair-deficient metastatic colorectal cancer: CheckMate 8HW subgroup analyses including treatment free status and outcomes in long-term survivors. Presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting; May 29–June 2; Chicago, IL, & Online.